Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease

Hyun Jung Lee, Jong Eun Yeon, Eun Jung Ko, Eileen L. Yoon, Sang Jun Suh, Keunhee Kang, Hae Rim Kim, Seoung Hee Kang, Yang Jae Yoo, Jihye Je, Beomjae Lee, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

AIM: To evaluate the inflammasome activation and the effect of peroxisome proliferator-activated receptors (PPAR)-δ agonist treatment in nonalcoholic fatty liver disease (NAFLD) models. METHODS: Male C57BL/6J mice were classified according to control or high fat diet (HFD) with or without PPAR-δ agonist (GW) over period of 12 wk [control, HFD, HFD + lipopolysaccharide (LPS), HFD + LPS + GW group]. HepG2 cells were exposed to palmitic acid (PA) and/or LPS in the absence or presence of GW. RESULTS: HFD caused glucose intolerance and hepatic steatosis. In mice fed an HFD with LPS, caspase-1 and interleukin (IL)-1β in the liver were significantly increased. Treatment with GW ameliorated the steatosis and inhibited overexpression of pro-inflammatory cytokines. In HepG2 cells, PA and LPS treatment markedly increased mRNA of several nucleotide-binding and oligomerization domain-like receptor family members (NLRP3, NLRP6, and NLRP10), caspase-1 and IL-1β. PA and LPS also exaggerated reactive oxygen species production. All of the above effects of PA and LPS were reduced by GW. GW also enhanced the phosphorylation of AMPK-α. CONCLUSION: PPAR-δ agonist reduces fatty acidinduced inflammation and steatosis by suppressing inflammasome activation. Targeting the inflammasome by the PPAR-δ agonist may have therapeutic implication for NAFLD.

Original languageEnglish
Pages (from-to)12787-12799
Number of pages13
JournalWorld Journal of Gastroenterology
Volume21
Issue number45
DOIs
Publication statusPublished - 2015 Dec 7

Fingerprint

PPAR delta
Inflammasomes
High Fat Diet
Lipopolysaccharides
Peroxisome Proliferator-Activated Receptors
Palmitic Acid
Caspase 1
Hep G2 Cells
Interleukin-1
AMP-Activated Protein Kinases
Glucose Intolerance
Liver
Non-alcoholic Fatty Liver Disease
Inbred C57BL Mouse
Reactive Oxygen Species
Nucleotides
Phosphorylation
Cytokines
Inflammation
Messenger RNA

Keywords

  • Inflammasome
  • Nonalcoholic fatty liver disease
  • Nonalcoholic steatohepatitis
  • Nucleotide-binding and oligomerization domain-like receptor
  • Peroxisome proliferator-activated receptors delta

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. / Lee, Hyun Jung; Yeon, Jong Eun; Ko, Eun Jung; Yoon, Eileen L.; Suh, Sang Jun; Kang, Keunhee; Kim, Hae Rim; Kang, Seoung Hee; Yoo, Yang Jae; Je, Jihye; Lee, Beomjae; Kim, Ji Hoon; Seo, Yeon Seok; Yim, Hyung Joon; Byun, Kwan Soo.

In: World Journal of Gastroenterology, Vol. 21, No. 45, 07.12.2015, p. 12787-12799.

Research output: Contribution to journalArticle

Lee, Hyun Jung ; Yeon, Jong Eun ; Ko, Eun Jung ; Yoon, Eileen L. ; Suh, Sang Jun ; Kang, Keunhee ; Kim, Hae Rim ; Kang, Seoung Hee ; Yoo, Yang Jae ; Je, Jihye ; Lee, Beomjae ; Kim, Ji Hoon ; Seo, Yeon Seok ; Yim, Hyung Joon ; Byun, Kwan Soo. / Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. In: World Journal of Gastroenterology. 2015 ; Vol. 21, No. 45. pp. 12787-12799.
@article{689a1e07b4c645839d783ef101189fd1,
title = "Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease",
abstract = "AIM: To evaluate the inflammasome activation and the effect of peroxisome proliferator-activated receptors (PPAR)-δ agonist treatment in nonalcoholic fatty liver disease (NAFLD) models. METHODS: Male C57BL/6J mice were classified according to control or high fat diet (HFD) with or without PPAR-δ agonist (GW) over period of 12 wk [control, HFD, HFD + lipopolysaccharide (LPS), HFD + LPS + GW group]. HepG2 cells were exposed to palmitic acid (PA) and/or LPS in the absence or presence of GW. RESULTS: HFD caused glucose intolerance and hepatic steatosis. In mice fed an HFD with LPS, caspase-1 and interleukin (IL)-1β in the liver were significantly increased. Treatment with GW ameliorated the steatosis and inhibited overexpression of pro-inflammatory cytokines. In HepG2 cells, PA and LPS treatment markedly increased mRNA of several nucleotide-binding and oligomerization domain-like receptor family members (NLRP3, NLRP6, and NLRP10), caspase-1 and IL-1β. PA and LPS also exaggerated reactive oxygen species production. All of the above effects of PA and LPS were reduced by GW. GW also enhanced the phosphorylation of AMPK-α. CONCLUSION: PPAR-δ agonist reduces fatty acidinduced inflammation and steatosis by suppressing inflammasome activation. Targeting the inflammasome by the PPAR-δ agonist may have therapeutic implication for NAFLD.",
keywords = "Inflammasome, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Nucleotide-binding and oligomerization domain-like receptor, Peroxisome proliferator-activated receptors delta",
author = "Lee, {Hyun Jung} and Yeon, {Jong Eun} and Ko, {Eun Jung} and Yoon, {Eileen L.} and Suh, {Sang Jun} and Keunhee Kang and Kim, {Hae Rim} and Kang, {Seoung Hee} and Yoo, {Yang Jae} and Jihye Je and Beomjae Lee and Kim, {Ji Hoon} and Seo, {Yeon Seok} and Yim, {Hyung Joon} and Byun, {Kwan Soo}",
year = "2015",
month = "12",
day = "7",
doi = "10.3748/wjg.v21.i45.12787",
language = "English",
volume = "21",
pages = "12787--12799",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "45",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease

AU - Lee, Hyun Jung

AU - Yeon, Jong Eun

AU - Ko, Eun Jung

AU - Yoon, Eileen L.

AU - Suh, Sang Jun

AU - Kang, Keunhee

AU - Kim, Hae Rim

AU - Kang, Seoung Hee

AU - Yoo, Yang Jae

AU - Je, Jihye

AU - Lee, Beomjae

AU - Kim, Ji Hoon

AU - Seo, Yeon Seok

AU - Yim, Hyung Joon

AU - Byun, Kwan Soo

PY - 2015/12/7

Y1 - 2015/12/7

N2 - AIM: To evaluate the inflammasome activation and the effect of peroxisome proliferator-activated receptors (PPAR)-δ agonist treatment in nonalcoholic fatty liver disease (NAFLD) models. METHODS: Male C57BL/6J mice were classified according to control or high fat diet (HFD) with or without PPAR-δ agonist (GW) over period of 12 wk [control, HFD, HFD + lipopolysaccharide (LPS), HFD + LPS + GW group]. HepG2 cells were exposed to palmitic acid (PA) and/or LPS in the absence or presence of GW. RESULTS: HFD caused glucose intolerance and hepatic steatosis. In mice fed an HFD with LPS, caspase-1 and interleukin (IL)-1β in the liver were significantly increased. Treatment with GW ameliorated the steatosis and inhibited overexpression of pro-inflammatory cytokines. In HepG2 cells, PA and LPS treatment markedly increased mRNA of several nucleotide-binding and oligomerization domain-like receptor family members (NLRP3, NLRP6, and NLRP10), caspase-1 and IL-1β. PA and LPS also exaggerated reactive oxygen species production. All of the above effects of PA and LPS were reduced by GW. GW also enhanced the phosphorylation of AMPK-α. CONCLUSION: PPAR-δ agonist reduces fatty acidinduced inflammation and steatosis by suppressing inflammasome activation. Targeting the inflammasome by the PPAR-δ agonist may have therapeutic implication for NAFLD.

AB - AIM: To evaluate the inflammasome activation and the effect of peroxisome proliferator-activated receptors (PPAR)-δ agonist treatment in nonalcoholic fatty liver disease (NAFLD) models. METHODS: Male C57BL/6J mice were classified according to control or high fat diet (HFD) with or without PPAR-δ agonist (GW) over period of 12 wk [control, HFD, HFD + lipopolysaccharide (LPS), HFD + LPS + GW group]. HepG2 cells were exposed to palmitic acid (PA) and/or LPS in the absence or presence of GW. RESULTS: HFD caused glucose intolerance and hepatic steatosis. In mice fed an HFD with LPS, caspase-1 and interleukin (IL)-1β in the liver were significantly increased. Treatment with GW ameliorated the steatosis and inhibited overexpression of pro-inflammatory cytokines. In HepG2 cells, PA and LPS treatment markedly increased mRNA of several nucleotide-binding and oligomerization domain-like receptor family members (NLRP3, NLRP6, and NLRP10), caspase-1 and IL-1β. PA and LPS also exaggerated reactive oxygen species production. All of the above effects of PA and LPS were reduced by GW. GW also enhanced the phosphorylation of AMPK-α. CONCLUSION: PPAR-δ agonist reduces fatty acidinduced inflammation and steatosis by suppressing inflammasome activation. Targeting the inflammasome by the PPAR-δ agonist may have therapeutic implication for NAFLD.

KW - Inflammasome

KW - Nonalcoholic fatty liver disease

KW - Nonalcoholic steatohepatitis

KW - Nucleotide-binding and oligomerization domain-like receptor

KW - Peroxisome proliferator-activated receptors delta

UR - http://www.scopus.com/inward/record.url?scp=84948972849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948972849&partnerID=8YFLogxK

U2 - 10.3748/wjg.v21.i45.12787

DO - 10.3748/wjg.v21.i45.12787

M3 - Article

VL - 21

SP - 12787

EP - 12799

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 45

ER -